Cargando…

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study

AIM: Most patients with Alzheimer's disease (AD) experience poor food intake and/or loss of appetite, which accelerates cognitive impairment. Several reports have shown that rivastigmine improves appetite in AD patients. The present study investigated the efficacy of a rivastigmine transdermal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuno, Norifumi, Mori, Takahiro, Ishikawa, Ichiro, Bando, Nobuyasu, Park, Haeyoung, Matsumoto, Yoshito, Mori, Itsuko, Tanaka, Mariko, Hirano, Takayuki, Nakamura, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Original Articles: Epidemiology, Clinical Practice and Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850597/ https://www.ncbi.nlm.nih.gov/pubmed/30864298 http://dx.doi.org/10.1111/ggi.13644

Ejemplares similares

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
por: Kurz, A, et al.
Publicado: (2009)

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice
por: López-Pousa, Secundino, et al.
Publicado: (2013)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
por: Moretti, Davide V., et al.
Publicado: (2014)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
por: Kano, Osamu, et al.
Publicado: (2013)

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
por: Shimura, Hideki, et al.
Publicado: (2021)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting
por: Nazir, Ejaz, et al.
Publicado: (2010)

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
por: Vagenas, Vassileios, et al.
Publicado: (2015)

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions
por: Adler, G, et al.
Publicado: (2014)

Preparation and Characterization of Rivastigmine Transdermal Patch Based on Chitosan Microparticles
por: Sadeghi, Mohsen, et al.
Publicado: (2016)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
por: Ismail, Manal Fouad, et al.
Publicado: (2013)

Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara, Chathuri, et al.
Publicado: (2021)

Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch
por: Knudtzen, Fredrikke C., et al.
Publicado: (2013)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011)

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis
por: Ferris, Steven, et al.
Publicado: (2013)

Effects of Rivastigmine on Brain Functional Networks in Patients With Alzheimer Disease Based on the Graph Theory
por: Zhang, Jiangtao, et al.
Publicado: (2021)

Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease
por: Vicente-Zurdo, David, et al.
Publicado: (2022)

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study
por: Muñoz-Moreno, Jose A., et al.
Publicado: (2017)

Polymeric Microneedles for Transdermal Delivery of Rivastigmine: Design and Application in Skin Mimetic Model
por: Guimarães, Tânia M. T., et al.
Publicado: (2022)

Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007)

EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*
por: Gauthier, S, et al.
Publicado: (2007)

Correction: Rivastigmine attenuates the Alzheimer's disease related protein degradation and apoptotic neuronal death signaling
Publicado: (2022)

Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease
por: Zhou, Yi, et al.
Publicado: (2023)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
por: Kim, Yong Kyun, et al.
Publicado: (2014)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)

Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease
por: Furiya, Yoshiko, et al.
Publicado: (2018)

MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer’s Disease Therapy
por: Shamsi, Anas, et al.
Publicado: (2020)

Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients
por: Zamani, M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_l0k7uehkt5gs8kd9gifcg187vk